DUBAI-INTERNET-CITY
20.10.2015 13:21:15 CEST | Business Wire | Press release
Dubai Internet City (DIC) , the official partner for the Smart City App Hack, has announced the competition’s 10 finalists; Boxit.com, Ithal, Einvite, Carpool Arabia, World Spotlight, D2D Auto Services, LupUp, GPSShield, MyGreenRank and App3ad. The competition is part of DIC’s role as a Strategic Partner for Smart Dubai, to support the development of UAE start-ups and app developers and bring together the tech community and foster innovation and creativity.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151020005876/en/
Over the past five months, developers and entrepreneurs have had the chance to be involved in the building of a truly Smart City and have created and developed apps, mentored by a global team of tech experts. Applicants were invited to submit app ideas based around five Smart themes; Urban Mobility, Energy and Emissions, Culture and Tourism, Retail and Shopping and Collaborative City, ahead of selection on 3 October.
The winning team will be awarded a trip to Barcelona to pitch their app at the Smart City Expo in November, as well as in5 membership, and second and third place will be awarded four months of membership at in5, and the chance to be selected as one of the finalists to pitch their apps in Barcelona. The winner of the Smart City Expo will be invited to pitch at the MasterCard Masters of Code in Silicon Valley.
Majed Al Suwaidi, Managing Director of Dubai Internet City and Dubai Outsource Zone said;
“The Smart City App Hack competition is part of our wider focus on supporting the development of UAE start-ups, entrepreneurs, mobile application and web developers. Competitions such as this are instrumental in achieving Dubai’s wider smart objectives and will contribute to the government’s vision to make Dubai the smartest place in the world by 2017.”
To register for the competition, please visit http://dubai.smartcityapphack.com/
About Dubai Internet City
Dubai Internet City (DIC), part of TECOM Group, a member of Dubai Holding, is the Middle East and North Africa’s largest ICT hub. Since the year 2000, DIC has successfully developed a prosperous ecosystem for technology organisations and today is home to Fortune 500 listed companies and multinationals as well as some of the region’s most dynamic and successful technology SMEs and start-ups from all elements of the ICT value chain.
DIC provides a wide range of facilities including state-of-the-art offices, a robust IT infrastructure, 24-hour security, retail services and hotels, spread across the business park’s unique and tranquil landscape; an environment that helps ICT businesses develop, innovate and grow.
For more information, please visit: www.dubaiinternetcity.com .
*Source: ME NewsWire
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020005876/en/
Contact:
For Dubai Internet City
Alexa Hooft Graafland, +971-55-559-7404
AHooftGraafland@bell-pottinger.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom